MELLITUS, LLC
Point-of-care urine test for glycated CD59 (GCD59) biomarker to screen, diagnose, and monitor diabetes and pre-diabetes
- Sector
- Medtech
- Headquarters
- Boston, MA
- Founded
- 2011
- Latest Form D
- $90K, Aug 2023
- Total capital
- $20.4M
- Federal grants
- $3.6M
- 4 awards · 2019–2021
- Rank in peer group#63 of 112
- Private capital raised
- $16.8M
- 11 Form D · last Aug 2023
- 38 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 7 pending · first 2024
- Rank in peer group#34 of 112
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 11th filing$90K
- Federal grantHealth and Human S · Phase II · Urine glycated CD59 as novel diabetes biomarker amenable to measure with a point-of-care device$1M
- Federal grantHealth and Human S · Phase II · Urine glycated CD59 as novel diabetes biomarker amenable to measure with a point-of-care device$1M
- Federal grantHealth and Human S · Phase II · An automated test for gestational diabetes based on glycated CD59$818K
- Federal grantHealth and Human S · Phase II · An automated test for gestational diabetes based on glycated CD59$751K
- Private capital raisedForm D · SEC · 10th filing$2.8M
- Private capital raisedForm D · SEC · 9th filing$1.7M
- Private capital raisedForm D · SEC · 8th filing$1.7M
- Private capital raisedForm D · SEC · 7th filing$5.6M
- Private capital raisedForm D · SEC · 6th filing$912K
- Private capital raisedForm D · SEC · 5th filing$993K
- Private capital raisedForm D · SEC · 4th filing$50K
- Private capital raisedForm D · SEC · 3rd filing$150K
- Private capital raisedForm D · SEC · 2nd filing$559K
- Private capital raisedForm D · SEC · 1st filing$2.2M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 112 peers
Line = medianMedtech · Instrument
- Federal grantsBelow median
- Granted patents#34 · top 30%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Michael A. ChorevResearcherDirectorLinked by 1 patent
- Christopher A. de SouzaDirectorNamed in SEC Form D filings
- Edwin Henrie, IIDirectorNamed in SEC Form D filings
- Ellie A. McGuireDirectorNamed in SEC Form D filings
- Gail PageDirectorNamed in SEC Form D filings
- John TagliamonteExecutive Officer, DirectorNamed in SEC Form D filings
Show all 9 people
- Jose HalperinDirectorNamed in SEC Form D filings
- Joyce A. LonerganExecutive Officer, DirectorNamed in SEC Form D filings
- Xing A. ZhaoDirectorNamed in SEC Form D filings
What it has protected
USPTO · 1 granted of 8- GrantedANTI-CD59 AntibodiesUSPTOUS 11,866,506
- PendingMethods And Reagents For Protein AnalysisUSPTOApplication 63188250
- PendingMethods And Antibodies For Diabetes-related ApplicationsUSPTOApplication PCTUS2018027856
Show all 8 patent records
- ANTI-CD59 AntibodiesJan 9, 2024 · US 11,866,506Granted
- Methods And Reagents For Protein AnalysisApplication 63188250Pending
- Methods And Antibodies For Diabetes-related ApplicationsApplication PCTUS2018027856Pending
- Methods And Reagents For The Assessment Of Gestational DiabetesApplication PCTUS2023022709Pending
- Methods And Reagents For The Assessment Of Gestational DiabetesApplication 63343493Pending
- Methods And Antibodies For Diabetes-related ApplicationsApplication 62488346Pending
- Methods And Reagents For Protein AnalysisApplication 63188252Pending
- Methods And Reagents For The Assessment Of Gestational DiabetesApplication 61945860Pending
Related companies, and why
- NEXTSTEP ROBOTICS, INC.Similar federal contract value in Medtech · null in contracts
- Vixiar Medical, IncSimilar federal contract value in Medtech · null in contracts
- POWELL MANSFIELD, INC.Similar federal contract value in Medtech · null in contracts
- HELIXBIND, INC.Similar federal contract value in Medtech · null in contracts
- HARMONUS, INC.Similar federal contract value in Medtech · null in contracts
- EARLY IS GOOD INC.Similar federal contract value in Medtech · null in contracts
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .